Phaseline

Companies › XellSmart Bio-Pharmaceutical (Suzhou)

XellSmart Bio-Pharmaceutical (Suzhou): clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XS228CN
Human allogeneic iPSC-derived motor neuron progenitor cells
–Phase 1Amyotrophic Lateral Sclerosis (ALS)Jan 2027
XS228
Allogeneic human induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cell
–Phase 1Spinal Cord InjuryFeb 2028
XS411
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenit
–Phase 1Parkinson Disease (PD)Mar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07118319XS228CNPhase 1Amyotrophic Lateral Sclerosis (ALS)NeurologyJan 2027
NCT06976229XS228Phase 1Spinal Cord InjuryNeurologyFeb 2028
NCT07166757XS411Phase 1Parkinson Disease (PD)NeurologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.